This study reveals the dynamic mechanisms of BCMA and GPRC5D antigen loss under immunotherapeutic pressure, providing critical evidence for designing multi-antigen targeting or combination therapeutic strategies. It highlights the need for early assessment of antigen stability in multiple myeloma to optimize the timing of clinical interventions.
Literature Overview
This article, titled 'The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D,' published in the journal Leukemia, systematically investigates the genomic evolutionary pathways of hepta-refractory multiple myeloma (MM). Using whole-genome sequencing (WGS) combined with immunohistochemistry (IHC), the study reveals that stepwise loss of BCMA, GPRC5D, and CD38 antigens is a central mechanism driving disease progression under consecutive immunotherapeutic pressure. The authors further demonstrate that antigen loss is driven not only by biallelic deletions but also involves complex subclonal heterogeneity and epigenetic regulation, underscoring the diversity of resistance mechanisms.Background Knowledge
Multiple myeloma is a highly heterogeneous plasma cell malignancy. Although CD38 antibodies, immunomodulatory drugs (IMiDs), and proteasome inhibitors have significantly improved patient survival in recent years, most patients eventually develop refractory disease. With the widespread use of BCMA- and GPRC5D-targeted CAR-T cells and bispecific T-cell engagers (TCEs), a novel form of 'hepta-refractory' MM—resistant to CD38, IMiDs, PIs, and both BCMA- and GPRC5D-targeted therapies—is emerging, associated with a dismal prognosis and a median overall survival of only 12.8 months. While BCMA-targeted therapies are initially effective, antigen escape has become a major resistance mechanism, including TNFRSF17 gene deletions, mutations, or transcriptional silencing. Similarly, GPRC5D, as an emerging target, has poorly defined mechanisms of antigen loss. This study focuses on systematically characterizing the genomic landscape of hepta-refractory MM to uncover the molecular basis and evolutionary trajectories of antigen loss, offering new insights into overcoming therapy resistance.
Research Methods and Experiments
The study included 37 patients with hepta-refractory MM, who had received a median of nine lines of therapy. Longitudinal samples from 17 patients were analyzed using WGS, complemented by IHC for antigen expression validation. WGS was performed on CD138+ plasma cells with a mean coverage of 107x, enabling detection of SNVs, Indels, CNVs, and structural variants. Clonal evolution was analyzed using MOBSTER and clonevol to construct phylogenetic trees. IHC staining with anti-BCMA antibody (E6D7B) was used to evaluate membrane expression in bone marrow or extramedullary lesions. Key experimental designs included deep WGS analysis of BCMA and GPRC5D loci, combined with IHC to distinguish between genetic deletions and non-genetic mechanisms of antigen loss. Longitudinal sampling revealed a branching evolutionary pattern rather than linear progression, demonstrating that resistant clones continue to evolve even after deep remission.Key Conclusions and Perspectives
Research Significance and Prospects
This study provides clear directions for drug development: novel T-cell therapies that do not rely on BCMA or GPRC5D—such as those targeting alternative antigens like FCRL5 or GPRC6A—should be developed. Additionally, combination therapies using bispecific or trispecific antibodies targeting multiple antigens may delay antigen escape. In terms of clinical monitoring, it is recommended to perform combined WGS and IHC at baseline and upon progression during CAR-T or TCE therapy to dynamically assess antigen integrity and guide re-challenge strategies. For disease modeling, animal models that simulate antigen loss evolution—such as conditionally knocking out BCMA and GPRC5D in MM models—are needed to test the anti-escape efficacy of novel immunotherapies.
Conclusion
Hepta-refractory multiple myeloma represents an extreme manifestation of current therapeutic bottlenecks, with its evolution characterized by the sequential loss of BCMA, GPRC5D, and CD38. Driving forces include biallelic inactivation, subclonal heterogeneity, and non-genetic regulation. This study emphasizes that single-target CAR-T or TCE therapies will inevitably face antigen escape, and future strategies must shift toward multi-targeted synergistic interventions. From bench to bedside, these findings support early evaluation of antigen stability at the onset of treatment and promote the development of immunotherapies independent of traditional targets. Furthermore, generating animal models that simulate dynamic antigen loss—such as humanized BCMA/GPRC5D double-knockout MM models—will accelerate novel drug screening. Ultimately, integrating genomic and protein expression profiling into precision diagnostic pathways holds promise for delivering more durable clinical benefits to multiple myeloma patients and reshaping the care paradigm for refractory disease.
